Market Exclusivity "Give-Away" Gone In Bioterror Bill
The contentious "wildcard" provision for market exclusivity has been removed prior to a vote from an updated Biodefense bill on Capitol Hill, easing concerns of the generic drug industry while leaving...To view the full article, register now.
Already a subscriber? Click here to view full article